Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089510050> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2089510050 endingPage "n/a" @default.
- W2089510050 startingPage "n/a" @default.
- W2089510050 abstract "Background and purpose In this first study of inhaled apomorphine (VR040) in patients with Parkinson's disease, the primary objective was to find the minimum efficacious dose of apomorphine that was useful in rescuing patients during ‘off’ periods. Safety, tolerability and pharmacokinetics of inhaled apomorphine were assessed during the study. Methods A double-blind, placebo-controlled, randomized trial of three escalating single doses of inhaled apomorphine (0.2, 0.5 and 0.8 mg fine particle dose) versus placebo (3 : 1 active:placebo) was performed. Parkinson's motor severity assessments by a clinician, and disease state assessment by the patient, were performed at baseline during an ‘off’ state, and at specified times after test drug administration. Safety assessments (including vital signs, electrocardiogram and forced expiratory volume) were performed, and plasma apomorphine levels measured. Results All 24 patients completed the study, and considering the three dose levels together, inhaled apomorphine did not significantly increase the proportion of patients switching from ‘off’ to ‘on’ (0/6 at 0.2 mg, 3/6 at 0.5 mg and 2/6 at 0.8 mg vs. 1/6 for placebo), or decrease the time from ‘off’ to ‘on’ post-treatment (10 min for 0.5 mg, 40 min for 0.8 mg, vs. 20 min for placebo). However, there was a suggestion of benefit at the higher doses (5/12 switched ‘on’ at the 0.5 or 0.8 mg doses, vs. 1/6 for placebo). There were no serious adverse events and treatment was well tolerated. Peak plasma concentration was 1–3 min post-dose, and plasma level dose proportionality was observed. Conclusions Inhaled apomorphine was safe and well tolerated at the doses tested for an acute challenge to rescue ‘off’ periods, but efficacy at these doses was limited. A follow-up study at higher doses is appropriate given these initial findings." @default.
- W2089510050 created "2016-06-24" @default.
- W2089510050 creator A5032765325 @default.
- W2089510050 creator A5038933985 @default.
- W2089510050 creator A5059872338 @default.
- W2089510050 creator A5059941306 @default.
- W2089510050 date "2013-01-01" @default.
- W2089510050 modified "2023-10-02" @default.
- W2089510050 title "Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson's disease" @default.
- W2089510050 cites W1977066187 @default.
- W2089510050 cites W1985047864 @default.
- W2089510050 cites W1988284593 @default.
- W2089510050 cites W1990549248 @default.
- W2089510050 cites W2000914933 @default.
- W2089510050 cites W2008560062 @default.
- W2089510050 cites W2013110094 @default.
- W2089510050 cites W2014583561 @default.
- W2089510050 cites W2020800817 @default.
- W2089510050 cites W2053622128 @default.
- W2089510050 cites W2060937140 @default.
- W2089510050 cites W2065351367 @default.
- W2089510050 cites W2071608414 @default.
- W2089510050 cites W2108525244 @default.
- W2089510050 cites W2132528735 @default.
- W2089510050 cites W2133425680 @default.
- W2089510050 cites W2169161939 @default.
- W2089510050 doi "https://doi.org/10.1111/ene.12091" @default.
- W2089510050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23350812" @default.
- W2089510050 hasPublicationYear "2013" @default.
- W2089510050 type Work @default.
- W2089510050 sameAs 2089510050 @default.
- W2089510050 citedByCount "12" @default.
- W2089510050 countsByYear W20895100502013 @default.
- W2089510050 countsByYear W20895100502015 @default.
- W2089510050 countsByYear W20895100502016 @default.
- W2089510050 countsByYear W20895100502019 @default.
- W2089510050 countsByYear W20895100502020 @default.
- W2089510050 countsByYear W20895100502021 @default.
- W2089510050 countsByYear W20895100502022 @default.
- W2089510050 crossrefType "journal-article" @default.
- W2089510050 hasAuthorship W2089510050A5032765325 @default.
- W2089510050 hasAuthorship W2089510050A5038933985 @default.
- W2089510050 hasAuthorship W2089510050A5059872338 @default.
- W2089510050 hasAuthorship W2089510050A5059941306 @default.
- W2089510050 hasConcept C112705442 @default.
- W2089510050 hasConcept C126322002 @default.
- W2089510050 hasConcept C137183658 @default.
- W2089510050 hasConcept C142724271 @default.
- W2089510050 hasConcept C197934379 @default.
- W2089510050 hasConcept C204787440 @default.
- W2089510050 hasConcept C27081682 @default.
- W2089510050 hasConcept C2777525119 @default.
- W2089510050 hasConcept C2778375690 @default.
- W2089510050 hasConcept C2779134260 @default.
- W2089510050 hasConcept C2779734285 @default.
- W2089510050 hasConcept C42219234 @default.
- W2089510050 hasConcept C513476851 @default.
- W2089510050 hasConcept C71924100 @default.
- W2089510050 hasConceptScore W2089510050C112705442 @default.
- W2089510050 hasConceptScore W2089510050C126322002 @default.
- W2089510050 hasConceptScore W2089510050C137183658 @default.
- W2089510050 hasConceptScore W2089510050C142724271 @default.
- W2089510050 hasConceptScore W2089510050C197934379 @default.
- W2089510050 hasConceptScore W2089510050C204787440 @default.
- W2089510050 hasConceptScore W2089510050C27081682 @default.
- W2089510050 hasConceptScore W2089510050C2777525119 @default.
- W2089510050 hasConceptScore W2089510050C2778375690 @default.
- W2089510050 hasConceptScore W2089510050C2779134260 @default.
- W2089510050 hasConceptScore W2089510050C2779734285 @default.
- W2089510050 hasConceptScore W2089510050C42219234 @default.
- W2089510050 hasConceptScore W2089510050C513476851 @default.
- W2089510050 hasConceptScore W2089510050C71924100 @default.
- W2089510050 hasLocation W20895100501 @default.
- W2089510050 hasLocation W20895100502 @default.
- W2089510050 hasOpenAccess W2089510050 @default.
- W2089510050 hasPrimaryLocation W20895100501 @default.
- W2089510050 hasRelatedWork W1830687917 @default.
- W2089510050 hasRelatedWork W1966047811 @default.
- W2089510050 hasRelatedWork W2003042623 @default.
- W2089510050 hasRelatedWork W202460821 @default.
- W2089510050 hasRelatedWork W2068849886 @default.
- W2089510050 hasRelatedWork W2074207917 @default.
- W2089510050 hasRelatedWork W2147606462 @default.
- W2089510050 hasRelatedWork W4205587618 @default.
- W2089510050 hasRelatedWork W4296087748 @default.
- W2089510050 hasRelatedWork W4366822339 @default.
- W2089510050 isParatext "false" @default.
- W2089510050 isRetracted "false" @default.
- W2089510050 magId "2089510050" @default.
- W2089510050 workType "article" @default.